Optimizing Patient-Centered Care for Relapsed/Refractory CLL With the Latest Evidence and Guideline Updates: Precision Education With Real-world Insights

In this ondemand webcast an expert reviews contemporary treatment strategies for relapsedrefractory chronic lymphocytic leukemiasmall lymphocytic lymphoma CLLSLL with an emphasis on how prior therapy mechanisms of resistance comorbidities disease characteristics and patient preferences inform treatment sequencing The faculty examines evidence supporting covalent and noncovalent BTK inhibitors BCL2 inhibitorbased regimens and retreatment approaches discusses pivotal trials including MURANO ELEVATERR ALPINE and the BRUIN CLL studies and addresses the evolving role of pirtobrutinib and CAR Tcell therapy for patients with increasingly treatmentresistant disease The activity also reviews practical management of treatmentrelated toxicities including tumor lysis syndrome bleeding atrial fibrillation hypertension and infusion reactions as well as strategies to prevent disease flare when transitioning between therapies Finally emerging approaches such as BTK degraders and bispecific antibodies are considered alongside patientcentered factors providing learners with a framework for individualizing therapy across successive lines of CLLSLL treatment

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

On-demand / recorded video
includes Article / monograph / reference
Credit · Up to 1 credit
MOC · Up to 1 point
Commercial Support

Released

Sep 8, 2026
Last day to claim credit

Mar 8, 2027 5 months left

Optimizing Patient-Centered Care for Relapsed/Refractory CLL With the Latest Evidence and Guideline Updates: Precision Education With Real-world Insights

Related courses

More from Clinical Care Options, LLC (dba Decera Clinical Education)